Zusammenfassung
Hintergrund
Mittels eines umfangreichen Fragebogens wurde die Versorgungssituation von 270 an interstitieller Zystitis (IC, „bladder pain syndrome“) erkrankten Patienten in Deutschland erfasst. Trotz umfangreicher Literatur zur IC (62.000 Literaturstellen in PubMed) ist über den Versorgungsalltag und die Qualität der Patientenversorgung fast nichts bekannt.
Ergebnisse
Die Patienten sind zu 94 % weiblich, zu 6 % männlich. Das Durchschnittsalter der Frauen beträgt 53,5 Jahre, das der Männer 67,0 Jahre. Die Patienten fühlen sich zu 47,77 % über ihre Erkrankung gut bis sehr gut informiert – 75 % von ihnen wünschen sich aber weitergehende Informationen. Als Informationsquelle dient in vielen Fällen das Internet. Durch die sozialen Netzwerke wird der Informationsaustausch unter den Patienten voraussichtlich zunehmen. Die Diagnose IC wurde am häufigsten (62,22 %) durch Biopsie/histologische Untersuchung gestellt. Es folgen Urodynamik, Kaliumtest, Hydrodistension und Zystoskopie. Die durchschnittliche Diagnosedauer betrug 9 Jahre. 46,67 % der Patienten suchten über 20-mal einen Arzt auf, ehe die Diagnose gestellt wurde; 51,84 % der Patienten müssen pro Tag > 14-mal Wasser lassen. Pollakisurie, Nykturie und Schmerzen stehen an der Spitze der beklagten Beschwerden. Ein Viertel der Patienten klagt über eine Dranginkontinenz. Von oralen Medikamenten werden Schmerzmittel am häufigsten eingenommen (61,7 %), gefolgt von Pentosanpolysulfat, Antidepressiva, Antiepileptika, Krampflösern und Mitteln gegen Harndrang. In der Patienteneinschätzung des Behandlungserfolgs (sehr gut und gut geholfen) der oralen Medikamente führen Pentosanpolysulfat, Schmerzmittel, Antidepressiva und Antiepileptika. Zur Instillation in die Harnblase werden hauptsächlich Medikamente, die die Glycosaminauskleidung der Blase wieder herstellen, angewendet: Hyaluronsäure, Chondroitinsulfat, die Kombination von beiden und Pentosanpolysulfat. Bei der Patienteneinschätzung des Behandlungserfolgs (sehr gut und gut geholfen) der Instillationstherapie lautet die Reihung: Chondroitinsulfat (62,69 %), Hyaluronsäure (55,77 %), Kombination von beiden (53,66 %) und Pentosanpolysulfat (46,30 %). Überraschend häufig (bei 119 Patienten) wurde das EMDA-Verfahren („electromotive drug administration“) mit Gleichstromanwendung zur Medikamenteneinbringung in die Blasenwand genannt. Der Erfolg (sehr gut und gut geholfen) lag in der Selbsteinschätzung mit 61,34 % an der Spitze der intravesikalen Verfahren.
Schlussfolgerung
Im Vergleich aller medikamentöser Verfahren in der Selbsteinschätzung der Patienten liegt die Instillation von Medikamenten in die Harnblase mit 53,53 % sehr gut geholfen und spürbar geholfen bei 368 Nennungen vorn, gefolgt von speziellen invasiven Verfahren mit 50,56 % (n = 271), alternativen Therapien mit 41,11 % (n = 287) und oraler Medikation mit 39,75 % (n = 1024). Hyaluronsäure- und Chondroitinsulfatpräparate, die Kombination von beiden und Pentosanpolysulfat (oral und intravesikal) werden von den gesetzlichen Krankenkassen nicht erstattet. Über 40 % der damit Behandelten brachen daher aus Kostengründen die Therapie ab.
Abstract
Background
Using a comprehensive questionnaire the care situation of 270 patients with interstitial cystitis (IC) and bladder pain syndrome in Germany was recorded. Despite comprehensive literature on IC (62,000 citations in PubMed) almost nothing is known of the everyday care and quality of patient care in Germany.
Results
In total 94 % of the patients were women and 6 % men, the average age of women was 53.5 years and that of men 67 years and 47.77 % of the patients felt that they were well or very well informed about the disease whereby the internet was the source of information in many cases. The exchange of information among patients will increase further through social networks. The diagnosis of IC was made most frequently (62.22 %) by biopsy and histological examination followed by urodynamics, potassium test, hydrodistension and cystoscopy. The average duration of the diagnosis was 9 years, 46.67 % of the patients consulted a doctor more than 20 times before the diagnosis was made and 51.84 % had to pass water more than 14 times per day. Frequency, nocturia and pain were the leading symptoms and 25 % of the patients complained of urge incontinence. Among oral medications, analgesics were taken most frequently (61.7 %) followed by pentosan polysulphate, antidepressants, antiepileptic drugs, antispasmodics and remedies for urinary urgency. In the self-assessment of the success of treatment with oral medications (helped very well and well), pentosan polysulphate, analgesics, antidepressants and antiepileptic drugs were considered to be the best. Medications that restore the glucosamine lining of the bladder were used predominantly for instillation into the bladder included hyaluronic acid, chondroitin sulphate and a combination of both and pentosan polysulphate. In the self-assessment of the success of treatment with instillation therapy (helped very well or well) the order was: chondroitin sulphate (62.69 %), hyaluronic acid (55.77 %), a combination of both (53.66 %) and pentosan polysulphate (46.30 %). The electromotive drug administration (EMDA) procedure with the use of direct current to introduce medications into the bladder wall was mentioned surprisingly often, namely, in 119 patients. In the self-assessment success (helped very well or well) was considered the best for intravesical procedures with 61.34 %.
Conclusions
Compared with all drug procedures instillation of medications into the bladder was mentioned 368 times and was assessed by the patients as having helped very well and noticeably by 53.53 %, followed by special invasive procedures at 50.56 %/271 mentions, alternative therapies at 41.11 %/287 mentions and oral medication at 39.75 %/1,024 mentions. Hyaluronic acid and chondroitin sulphate products, the combination of both and pentosan polysulphate (oral and intravesical) are not reimbursed by the statutory health insurance. Over 40 % of patients treated with these therefore discontinued the treatment for reasons of cost.
Literatur
Andersen AV, Granlund P, Schultz A et al (2012) Long-term experience with surgical treatment of selected patients with bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol 46(4):284–289
Anderson RU, Orenberg EK, Morey A et al (2009) Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 182(5):2319–2324
Anger JT, Zabihi N, Clemens JQ, Payne CK et al (2011) Treatment choice, duration, and cost in patients with interstitial cystitis and painfull bladder syndrome. Int Urogynecol J 22(4):395–400
Bassaly R, Downes K, Hart S (2011) Dietary consumption triggers in interstitial cystitis/bladder pain syndrome patients. Female Pelvic Med Reconstr Surg 17(1):36–39
Berry SH, Elliot MN, Suttorp M et al (2011) Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 186(2):540–544
Blalock EM, Korrect GS, Stromberg AJ, Erickson DR (2012) Gene expression analysis of urine sediment: evaluation for potential noninvasive markers of interstitial cystitis/bladder pain syndrome. J Urol 187(2):725–732
BMBF (2010) Bildung in Deutschland 2010. Ein indikatorengestützter Bericht mit einer Analyse zu Perspektiven des Bildungswesens im demographischen Wandel. Kultusministerkonferenz, Bundesministerium für Bildung u. Forschung. Bertelsmann, München, DNB-Katalog der Deutschen Nationalbibliothek (http://dnb.ddb.de), ISBN 978–3-7639-1992-5
Bogart LM, Suttorp MJ, Elliot MN et al (2011) Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology 77(3):576–580
Butrick CW (2012) Interstitial cystitis/bladder pain syndrome: management of the pain disorder: a urogynecology perspective. Urol Clin North Am 39(3):377–387
Chelimsky G, Heller E, Buffington CA et al (2012) Co-morbidities of interstitial cystitis. Front Neuroscience 6:114
Cheng C, Rosamilia A, Healey M (2012) Diagnosis of interstitial cystitis/bladder pain syndrome in women with chronic pelvic pain: a prospective observational study. Int Urogyn J 23(10):1361–1366
Clemens JQ, Meenan RT, Rosetti MC et al (2008) Costs of interstitial cystitis in a managed care population. Urology 71(5):776–781
Clemens JQ, Bogart LM, Liu K et al (2011) Perceptions of „urgency“ in women with interstitial cystitis/bladder pain syndrome or overactive bladder. Neurourol Urodyn 30(3):402–405
Close CE, Carr MC, Burns MW et al (1996) Interstitial cystitis in children. J Urol 156(2):860–862
Corcoran AT, Yoshimura N, Tyagi V et al (2012) Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol 31(1):241–246
Daha LK, Riedl CR, Lazar D et al (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47(3):393–397
Engelhardt PF, Morakis N, Daha LK et al (2011) Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J 22(4):401–405
Evans RJ, Moldwin RM, Cossons N et al (2011) Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 185(5):1716–1721
Fall M, Baranowski AP, Eleneil S et al (2010) EAU guidelines on chronic pelvic pain. Eur Urol 57:35–48
Farmer M, Chanda ML, Parks EL et al (2011) Brain functional and anatomical changes in chronic prostatits/chronic pelvic pain syndrome. J Urol 186:117–124
Friedlander JI, Shorter B, Moldwin RM (2012) Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int 109(11):1584–1591
Gafni-Kane A, Botros SM, Du H et al (2013) Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J 24(2):303–311
Gardella B, Porru D, Nappi RE et al (2011) Interstitial cystitis is associated with vulvodynia and sexual dysfunction – a case-control study. J Sex Med 8(6):1726–1734
Giannantoni A, Cagini R, Del Zingaro M et al (2010) Botulinum A toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and Quality of Life. Curr Drug Deliv 7(5):442–446
Ginting JV, Tripp DA, Nickel JC et al (2011) Spousal support decreases the negative impact of pain on mental quality of life in women with interstitial cystitis/painful bladder syndrome. BJU Int 108(5):713–717
Glaeske G, Augustin M, Abholz H et al (2009) Epidemiologische Methoden für die Versorgungsforschung. Gesundheitswesen 71(10):685–693
Gottsch HP, Miller JL, Yang CC, Berger RE (2011) A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodyn 30(1):93–96
Ham BK, Kim JH, Oh MM et al (2012) Effects of combination treatment of intravesical resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial cystitis: a pilot study. Int Neurourol J 16(1):41–46
Hanley RS, Stoffel JT, Zagha RM et al (2009) Multimodal therapy for painful bladder syndrome/interstitial cystitis: pilot study combining behavioral, pharmacologic, and endoscopic therapies. Int Braz J Urol 35(4):467–474
Hanno PM, Burks DA, Clemens JQ et al (2011) AUA Guideline for the diagnosis and treatment of interstitial Cystitis/bladder pain syndrome. J Urol 185(6):2162–2170
Hepner KA, Watkins KE, Elliot MN et al (2012) Suicidal ideation among patients with bladder pain syndrome/interstitial cystitis. Urology 80(2):280–285
Hill JR, Isom-Batz G, Panagopoulos G et al (2008) Patient perceived outcomes of treatments used for interstitial cystitis. Urology 71(1):62–66
Hoffmann F, Huber J (2011) Die Urologie braucht Versorgungsforschung. Urologe 50:678–684
Homma Y, Ueda T, Ito T et al (2009) Japanese guideline for diagnosis and treatment of interstitial cystitis. J Urol 16:4–16
Homma Y, Ueda T, Tomoe H et al (2009) Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. J Urol 16:597–615
Huber J, Peters D, Kessler A et al (2010) Selbsthilfe im Onlineforum bei lokal begrenztem Prostatakarzinom: Qualitative Analyse der Entscheidungsfindung. Urologe 49:1377–1384
Humphrey L, Arbuckle R, Moldwin R et al (2012) The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur Urol 61(2):271–279
Hung MJ, Chen YT, Shen PS et al (2012) Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J 23(11):1533–1539
Jocham B (2012) Lebensbilder von Frauen mit IC; Emotionale u. kognitive Elemente bei der Entstehung, Aufrechterhaltung u. Reduktion chronischer Schmerzen am Beispie IC/BPS. Dt. Nationalbibliographie der Deutschen Nationalbibliothek, Dissertation, http://dnb.d-nb.de
Kaneko G, Nishimoto K, Ito Y, Uchida A (2012) The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis. Can Urol Assoc J 6(2):46–49
Kang JH, Keller JJ, Chen YK, Lin HC (2012) Reflux esophagitis increased the risk of bladder pain syndrome/interstitial cystitis: A 3-year follow-up study. Neurourol Urodyn 21(11):1139–1143
Katz L, Tripp DA, Nickel JC et al (2012) Disability in women suffering from interstitial cystitis/bladder pain syndrome. BJU Int 111(1):114–121
Keay S, Leitzell S, Ochrzcin A et al (2012) A mouse model for interstitial cystitis/painful bladder pain syndrome based on APF inhibition of bladder epithelial repair: a pilot study. BMC Urol 12(1):17
Keller J, Chiou HY, Lin HC (2012) Increased risk of bladder cancer following diagnosis with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn 32(1):58–62
Konkle KS, Berry SH, Elliott MN et al (2012) Comparison of an interstitial cystits/bladder pain Syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis epidemiology study. J Urol 187(2):508–512
Koziol JA, Clark DC, Gittes RF, Tan EM (1993) The natural history of interstitial cystitis: a survey of 374 patients. J Urol 149(3):465–469
Kummervold PE, Chronaki CE, Lausen B et al (2008) e-Health trends in Europe 2005–2007: a population based survey. J Med Internet Res 10:42
Kuo YC, Kuo HC (2012) Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversenitivity in women. Int J Clin Pract 66(2):146–151
Lai MC, Kuo YC, Kuo HC (2012) Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens. Int J Urol, doi: 10.1111/j.1442-2042.2012.03135.x
Lee JD, Lee MH (2011) Increased expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor associated with glomerulation formation in patients with interstitial cystitis. Urology 78(4):971.11–15
Li GZ, Zhang N, Du P et al (2010) Risk factors for interstitial cystitis/painful bladder syndrome in patients with lower urinary tract symptoms: a Chinese multi-center study. Chin Med J (Engl) 123(20):2842–2846
Liu HT, Shie JH, Chen SH et al (2012) Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome. Urology 80(1):225
Logadottir Y, Fall M, Kabjörn-Gustafsson C, Peeker R (2012) Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis. Scand J Urol Nephr 46(5):365–370
Logadottir Y, Hallsberg L, Fall M et al (2012) Bladder pain syndrome/interstitial cystitis ESSIC type 3C: high expression of inducible nitric oxide synthase in inflammatory cells. Scand J Urol Nephr 47(1):52–56
Mayson BE, Teichman JM (2009) The relationship between sexual abuse and interstitial cystitis/painful bladder syndrome. Curr Urol Rep 10(6):441–447
Marinkovic SP, Gillen LM, Marinkovic CM (2011) Minimum 6-year outcomes for interstitial cystitis treated with sacral neuromodulation. Int Urogynecol J 22(4):407–412
Merwe JP van de, Nordling J, Bouchelouche P et al (2008) Diagnostic criteria, classification, and nomenclature for painfull bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 53:60–67
National Institute of Diabetes and Digestive and Kidney Diseases (2011) Interstitial cystitis/painful bladder syndrome. NIH publication no. 11–3220
Neuhaus J, Schulte-Baukloh H, Stolzenburg JU et al (2011) Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC). World J Urol 30(5):693–700
Nickel JC (2004) Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am 88(2):467–481
Nickel JC, Tripp D (2007) Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J Urol 177(5):1832–1836
Nickel JC, Shoskes DA, Irvine-Bird K (2010) Prevalence and impact of bacteriuria and/or urinary tract infection in interstitial cystitis/painful bladder syndrome. Urology 76(4):799–803
Nickel JC, Tripp DA, Pontari M et al (2010) Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urol 184(4):1358–1363
Nickel JC, Tripp DA, Pontari M et al (2011) Childhood sexual trauma in women with interstitial cystitis/bladder pain syndrome: a case control study. Can Urol Assoc J 5(6):410–415
Nickel JC, Jain P, Shore N et al (2012) Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med 4(143):143
Nickel JC, Hanno P, Kumar K, Thomas H (2012) Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology 79(6):1220–1224
Nordling J, Fall M, Hanno P (2011) Global concepts of bladder pain syndrome (interstitial cystitis). World J Urol 30(4):457–464
Nordling J, Fall M, Hanno P (2012) Global concepts of bladder pain syndrome (interstitial cystitis). World J Urol 30(4):457–464
Panzera AK, Reishtein J, Shewokis P (2011) Sleep disruption and interstitial cystitis symptoms in women. Urol Nurs 31(3):159–165
Parsons CL (2010) The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU int 107(3):370–375
Parsons CL, Zupkas P, Proctor J et al (2012) Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med 9(1):207–212
Peters KM, Carrico DJ, Diokno AC (2008) Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome. Urology 71(4):634–640
Peters KM, Killinger KA, Mounayer MH, Boura JA (2011) Are ulcerative and nonulcerative interstitial cystitis/painful bladder syndrome 2 distinct diseases? A study of coexisting conditions. Urology 78(2):301–308
Pfaff H, Neugebauer EA, Glaeske G, Schrappe M (Hrsg) (2011) Lehrbuch Versorgungsforschung. Schattauer, Stuttgart
Pontari MA, Ruggieri MR (2008) Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 179(Suppl 5):61–67
Porru D, Leva F, Parmigiani A et al (2012) Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J 23(9):1193–1199
Propert KJ, Payne C, Kusek JW et al (2002) Pitfalls in the design of clinical trials for interstitial cystitis. Urology 60(5):742–748
Quillin RB, Erickson DR (2012) Practical use of the New American Urological Association Interstitial Cystitis guidelines. Curr Urol Rep 13(5):394–401
Quillin RB, Erickson DR (2012) Management of interstitial cystitis/bladder pain syndrome: a urology perspective. Urol Clin North Am 39(3):389–396
Rais-Bahrami S, Friedlander JI, Herati AS et al (2012) Symptom profile variability of interstitial cystitis/painful bladder syndrome by age. BJU Int 109(9):1356–1359
Röllig C (2011) Grenzen der Versorgungsforschung. Urologe 50:697–701
Rothrock NE (2001) Stress and symptoms in patients with interstitial cystitis: a life stress model. Urology 57(3):422–427
Rovner ES, Kim ED (2011) Interstitial cystitis. http://emedicine.medscape.com/article/441831/overview
Sant GR (1997) Interstitial cystitis. Curr Opin Obstet Gynecol 9(5):332–336
Schwalenberg T, Stolzenburg JU, Ho TP et al (2012) Enhanced urothelial expression of human chorionic gonadotropin beta (hCGbeta) in bladder pain syndrome/interstitial cystitis (BPS/IC). World J Urol 30(3):411–417
Shie JH, Kuo HC (2011) Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 108(2):136–141
Shorter B, Lesser M, Moldwin RM, Kushner L (2007) Effect of comestibles on symptoms of interstitial cystitis. J Urol 178(1):145–152
Stav K, Berashvili I, Lindner A, Leibovici D (2012) Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology 80(1):61–65
Sugihara T, Yasunage H, Horiguchi H et al (2012) Admissions related to interstitial cystitits in Japan: an estimation based on the Japanes diagnosis procedure combination database. Int J Urol 19(1):86–89
Tunitsky E, Barber MD, Jeppson PC et al (2012) Bladder pain syndrome/interstitial cystitis in twin sisters. J Urol 187(1):148–152
Tyagi P, Killinger K, Tyagi V et al (2012) Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol 187(6):2243–2248
Vela Navarrete R, Enguita G (2012) Interstitial cystitis: one hundred years of mysteries and frustration. Timely Top Med Uro Int 14:7–90005
Walid MS, Heaton RL (2011) Interstitial cystitis and endometriosis in a 12-year-old girl. Arch Gynecol Obstet 283(1):115–117
Warren JW, Brown J, Tracy JK et al (2008) Evidence-based criteria for pain of interstitial cystitis/painful bladder syndrome in women. Urology 71(3):444–448
Warren JW, Brown V, Jacobs S et al (2008) Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology 71(6):1085–1090
Warren JW, Diggs C, Horne L, Greenberg P (2010) Interstitial cystitis/painful bladder syndrome: what do patients mean by „perceived“ bladder pain? Urology 77(2):309–312
Warren JW, Greenberg P, Diggs C et al (2010) A prospective early history of incident interstitial cystitis/painful bladder syndrome. J Urol 184(6):2333–2338
Warren JW, Wesselmann U, Morozov V, Langenberg PW (2011) Numbers and types of nonbladder syndromes as risk factors for interstitial cystitis/painfull bladder syndrome. Urology 77(2):313–319
Warren JW, Clauw DJ, Langenberg P (2012) Prognostic factors for recent-onset interstitial cystitis/painful bladder syndrome. BJU Int 21(11):1139–1143
Watkins KE, Eberhart N, Hilton L et al (2011) Depressive disorders and panic attacks in women with bladder pain syndrome/interstitial cystitis: a population-based sample. Gen Hosp Psychiatry 33(2):143–149
Weißbach L (2011) Standortverstimmung. Urologe 50:671
Wu EQ, Birnbaum H, Mareva M et al (2006) Interstitial cystitis – cost, treatment and co-morbidities in an employed population. Pharmacoeconomics 24(1):55–65
Wyllie MG (2010) Interstitial Cystitis: a negative ongoing situation? BJU int 106:1401–1402
Yoost JL, Hertweck SP, Loveless M (2012) Diagnosis and treatment of interstitial cystitis in adolescents. J Pediatr Adolesc Gynecol 25(3):162–171
Danksagung
Die Autoren danken allen Studienteilnehmern und der Firma FARCO-PHARMA GmbH für die finanzielle Unterstützung zur Durchführung dieser Studie. Diese Studie wäre ohne die Unterstützung des ICA Deutschland (Interstitial Cystitis Association Deutschland e. V.) und der Deutschen Kontinenz Gesellschaft e. V. nicht möglich gewesen.
Interessenkonflikt
Der korrespondierende Autor weist für sich und seine Koautoren auf folgende Beziehungen hin: PD Dr. med. Gert Froehlich ist als Berater für die Firma Farco-Pharma tätig. Prof. Dr. Dieter Jocham ist als Berater für die Firma Farco-Pharma tätig. Frank Sandig und Prof. Dr. Andreas Ziegler haben für das Datenmanagement und die statistische Analyse dieser Studie Honorare von der Firma Farco-Pharma erhalten.
Author information
Authors and Affiliations
Corresponding author
Additional information
Unter Mitarbeit von Prof. Dr. S. Störkel, Dr. R. Stratmeyer, Dr. A. Wördehoff, B. Mündner-Hensen und J. Hensen (ICA-Deutschland e. V.), Deutsche Kontinenz Gesellschaft e. V., G. Odenthal und K. Tobien (FARCO-PHARMA GmbH).
Rights and permissions
About this article
Cite this article
Jocham, D., Froehlich, G., Sandig, F. et al. Die Versorgungssituation von Patienten mit interstitieller Zystitis in Deutschland. Urologe 52, 691–702 (2013). https://doi.org/10.1007/s00120-013-3130-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-013-3130-8